Lite Strategy

Lite Strategy Days Payable Outstanding

The Days Payable Outstanding (DPO) of Lite Strategy (LITS) as of Nov 20, 2026 is 174.57. In the previous year, Days Payable Outstanding (DPO) was 3,019.11 — a change of -94.22% (lower).

Days Payable Outstanding

174.57

YoY

-94.22%

Last updated:

Days Payable Outstanding (DPO) of Lite Strategy is 2025 174.57 . Days Payable Outstanding (DPO) of Lite Strategy was 2024 3,019.11 . It decreases by -94.22% lower compared to the previous year.

The Lite Strategy Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2018
388.76 USD
Jan 1, 2019
411.27 USD
Jan 1, 2020
328.09 USD
Jan 1, 2021
1,647.43 USD
Jan 1, 2022
2,340.14 USD
Jan 1, 2023
1,233.56 USD
Jan 1, 2024
3,019.11 USD
Jan 1, 2025
174.57 USD
The Lite Strategy Days Payable Outstanding history
YEARDays Payable OutstandingYoY
174.57-94.22%
3,019.11+144.75%
1,233.56-47.29%
2,340.14+42.05%
1,647.43+402.13%
328.09-20.22%
411.27+5.79%
388.76+787.57%
43.80—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lite Strategy Stock analysis

What does Lite Strategy do? MEI Pharma, Inc. develops cancer therapies, focusing on clinical drug candidates including Pracinostat, ME-344, and ME-401. Pracinostat, an HDAC inhibitor for hematologic diseases like AML and MDS, has undergone Phase I and II trials. ME-344 targets mitochondrial components in rapidly proliferating cells, while ME-401 inhibits PI3K delta for hematologic cancer treatment. The company generates revenue through clinical development and potential future drug sales, targeting oncology markets with its pipeline of cancer therapies. The firm's products are developed for specific cancer indications, with Pracinostat tested in advanced hematologic malignancies and solid tumors. ME-344 and ME-401 address unmet needs in mitochondrial and PI3K delta pathways, respectively. MEI Pharma's revenue model relies on clinical trial progress and future commercialization of these therapies, aiming to secure partnerships or direct sales in oncology. MEI Pharma's portfolio includes three clinical drug candidates, each targeting distinct cancer mechanisms. Pracinostat is advanced in trials for AML and MDS, while ME-344 and ME-401 are in development for broader cancer applications. The company monetizes through potential drug approvals and sales, with a focus on hematologic cancers and solid tumor markets. Lite Strategy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lite Strategy stock

Days Payable Outstanding (DPO) of Lite Strategy is 174.57 in 2025.

Days Payable Outstanding (DPO) of Lite Strategy changed from 3,019.11 to 174.57, representing a -94.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Lite Strategy since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Lite Strategy with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Lite Strategy

All Key Metrics — Lite Strategy